Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tempest Therapeutics, Inc. - Common Stock
(NQ:
TPST
)
2.920
-0.070 (-2.34%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tempest Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
June 20, 2024
Via
Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
↗
June 20, 2024
Via
Benzinga
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
↗
June 20, 2024
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients...
Via
Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
↗
June 20, 2024
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday.
Via
InvestorPlace
Why Is Avrobio (AVRO) Stock Moving Today?
↗
June 20, 2024
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today.
Via
InvestorPlace
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
June 20, 2024
Via
Benzinga
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
↗
June 20, 2024
Tempest Therapeutics stock is up on Thursday with heavy trading of TPST shares ahead of a presentation taking place this morning.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 20, 2024
Via
Benzinga
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
June 20, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
June 20, 2024
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
June 19, 2024
Via
Benzinga
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
June 18, 2024
Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
May 31, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Tempest to Participate in Upcoming Investor Conferences
May 21, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024
↗
May 09, 2024
TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 26, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
April 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
April 05, 2024
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.
Via
Benzinga
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
April 04, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023
↗
March 19, 2024
TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Tempest Reports Year End 2023 Financial Results and Provides Business Update
March 19, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
March 14, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
March 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
March 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
February 26, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Therapeutics Announces Groundbreaking Advances in Liver Cancer Treatment, Showcasing Exceptional Efficacy and Safety Data at ASCO Annual Meeting 2024
January 30, 2024
Via
AB Newswire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
January 16, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.